Activation of interferon response through toll-like receptor 3 impacts viral pathogenesis and pulmonary toll-like receptor expression during respiratory syncytial virus and influenza infections in the cotton rat sigmodon hispidus model

Journal of Interferon and Cytokine Research

Volumn 30, Issue 4, 2010, Pages 229-241

  Boukhvalova, Marina S ^a   Sotomayor, Talia B ^a,b   Point, Ryan C ^a   Pletneva, Lioubov M ^a   Prince, Gregory A ^a   Blanco, Jorge C G ^a  

^a Virion Systems Inc   (United States)

^b WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; CHEMOKINE; CHEMOKINE GRO; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GENE PRODUCT; HILTONOL; INTERFERON; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; POLYINOSINIC POLYCYTIDYLIC ACID; PROTEIN MX 1; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 7; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; COTTON RAT; CYTOKINE RESPONSE; DISEASE MODEL; DOSE RESPONSE; DRUG DOSE COMPARISON; EXPERIMENTAL INFECTION; GENE EXPRESSION; HISTOPATHOLOGY; INFLUENZA; INFLUENZA VIRUS A; INTERFERON INDUCTION; LUNG ALVEOLUS MACROPHAGE; LUNG INFILTRATE; LUNG LAVAGE; LYMPHOCYTE; NEUTROPHIL; NONHUMAN; NUCLEOTIDE SEQUENCE; PNEUMONIA; PRIORITY JOURNAL; PROTEIN CONTENT; RAT; RESPIRATORY SYNCYTIAL VIRUS INFECTION; UPREGULATION; VIRUS LOAD; VIRUS VIRULENCE;

ANIMALS; BRONCHOALVEOLAR LAVAGE; CARBOXYMETHYLCELLULOSE; CHEMOKINES; DISEASE MODELS, ANIMAL; GENE EXPRESSION REGULATION; INFLUENZA A VIRUS; INTERFERONS; LUNG; MICE; ORTHOMYXOVIRIDAE INFECTIONS; PNEUMONIA; POLY I-C; POLYLYSINE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; SIGMODONTINAE; TOLL-LIKE RECEPTOR 3; VIRAL LOAD;

ANIMALIA; MURINAE; MUS; ORTHOMYXOVIRIDAE; RESPIRATORY SYNCYTIAL VIRUS; RICE STRIPE VIRUS; SIGMODON; SIGMODON HISPIDUS;

EID: 77952534501     PISSN: 10799907     EISSN: None     Source Type: Journal    
DOI: 10.1089/jir.2009.0025     Document Type: Article

References (58)

1. Akira S, Uematsu S, Takeuchi O. 2006. Pathogen recognition and innate immunity. Cell 124:783-801.
2. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. 2001. Recognition of double-stranded RNA and activation of NF-kappaB by Tolllike receptor 3. Nature 413:732-738.
3. Bhoj VG, Sun Q, Bhoj EJ, Somers C, Chen X, Torres J P, Mejias A, Gomez AM, Jafri H, Ramilo O, Chen ZJ. 2008. MAVS and MyD88 are essential for innate immunity but not cytotoxic T lymphocyte response against respiratory syncytial virus. Proc Natl Acad Sci USA 105:14046-14051.
4. Blanco JC, Pletneva L, Boukhvalova M, Richardson JY, Harris KA, Prince GA. 2004. The cotton rat: an underutilized animal model for human infectious diseases can now be exploited using specific reagents to cytokines, chemokines, and interferons. J Interferon Cytokine Res 24:21-28.
5. Blanco JC, Richardson JY, Darnell ME, Rowzee A, Pletneva L, Porter DD, Prince GA. 2002. Cytokine and chemokine gene expression after primary and secondary respiratory syncytial virus infection in cotton rats. J Infect Dis 185:1780-1785.
6. Boukhvalova MS, Prince GA, Blanco JC. 2007a. Respiratory syncytial virus infects and abortively replicates in the lungs in spite of preexisting immunity. J Virol 81:9443-9450.
7. Boukhvalova MS, Yim KC, Kuhn KH, Hemming JP, Prince GA, Porter DD, Blanco JC. 2007b. Age-related differences in pulmonary cytokine response to respiratory syncytial virus infection: modulation by anti-inflammatory and antiviral treatment. J Infect Dis 195:511-518.
8. Brodsky I, Strayer DR, Krueger LJ, Carter WA. 1985. Clinical studies with ampligen (mismatched double-stranded RNA). J Biol Response Mod 4:669-675. (Pubitemid 16209277)
9. Cameron MJ, Ran L, Xu L, Danesh A, Bermejo-Martin JF, Cameron CM, Muller M P, Gold WL, Richardson SE, Poutanen SM, Willey BM, DeVries ME, Fang Y, Seneviratne C, Bosinger SE, Persad D, Wilkinson P, Greller LD, Somogyi R, Humar A, Keshavjee S, Louie M, Loeb MB, Brunton J, McGeer AJ, Kelvin DJ. 2007. Interferon-mediated immunopathological events are associated with atypical innate and adaptive immune responses in patients with severe acute respiratory syndrome. J Virol 81:8692-8706.
10. De Clercq E. 1981. Interferon induction by polynucleotides, modified polynucleotides, and polycarboxylates. Methods Enzymol 78:227-236.
11. de Jong MD, Simmons CP, Thanh TT, Hien VM, Smith GJ, Chau TN, Hoang DM, Chau NV, Khanh TH, Dong VC, Qui PT, Cam BV, Ha do Q, Guan Y, Peiris JS, Chinh NT, Hien TT, Farrar J. 2006. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med 12:1203-1207.
12. Didierlaurent A, Goulding J, Hussell T. 2007. The impact of successive infections on the lung microenvironment. Immunology 122:457-465.
13. Fang J, Bredow S, Taishi P, Majde JA, Krueger JM. 1999. Synthetic influenza viral double-stranded RNA induces an acute-phase response in rabbits. J Med Virol 57:198-203.
14. Groskreutz DJ, Monick MM, Powers LS, Yarovinsky TO, Look DC, Hunninghake GW. 2006. Respiratory syncytial virus induces TLR3 protein and protein kinase R, leading to increased double-stranded RNA responsiveness in airway epithelial cells. J Immunol 176:1733-1740.
15. Guerrero-Plata A, Baron S, Poast JS, Adegboyega PA, Casola A, Garofalo R P. 2005. Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections. J Virol 79:10190-10199.
16. Guillot L, Le Goffic R, Bloch S, Escriou N, Akira S, Chignard M, Si-Tahar M. 2005. Involvement of toll-like receptor 3 in the immune response of lung epithelial cells to double-stranded RNA and influenza A virus. J Biol Chem 280:5571-5580.
17. Gupta CK, Leszczynski J, Gupta RK, Siber GR. 1996. Stabilization of respiratory syncytial virus (RSV) against thermal inactivation and freeze-thaw cycles for development and control of RSV vaccines and immune globulin. Vaccine 14:1417-1420.
18. Haeuber D. 1989. Recent advances in the management of biotherapy-related side effects: flu-like syndrome. Oncol Nurs Forum 16:35-41.
19. Hayashi F, Means TK, Luster AD. 2003. Toll-like receptors stimulate human neutrophil function. Blood 102:2660-2669.
20. Haynes LM, Moore DD, Kurt-Jones EA, Finberg RW, Anderson LJ, Tripp RA. 2001. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J Virol 75:10730-10737.
21. Jewell NA, Vaghefi N, Mertz SE, Akter P, Peebles RS, Jr., Bakaletz LO, Durbin RK, Flano E, Durbin JE. 2007. Differential type I interferon induction by respiratory syncytial virus and influenza a virus in vivo. J Virol 81:9790-9800.
22. Johnson TR, Mertz SE, Gitiban N, Hammond S, Legallo R, Durbin RK, Durbin JE. 2005. Role for innate IFNs in determining respiratory syncytial virus immunopathology. J Immunol 174:7234-7241.
23. Jones A, Qui JM, Bataki E, Elphick H, Ritson S, Evans GS, Everard ML. 2002. Neutrophil survival is prolonged in the airways of healthy infants and infants with RSV bronchiolitis. Eur Respir J 20:651-657.
24. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T, Akira S. 2006. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441:101-105.
25. Levy HB, Baer G, Baron S, Buckler CE, Gibbs CJ, Iadarola MJ, London WT, Rice J. 1975. A modified polyriboinosinic-polyribocytidylic acid complex that induces interferon in primates. J Infect Dis 132:434-439.
26. Lindemans CA, Coffer PJ, Schellens IM, de Graaff PM, Kimpen JL, Koenderman L. 2006. Respiratory syncytial virus inhibits granulocyte apoptosis through a phosphatidylinositol 3-kinase and NF-kappaB-dependent mechanism. J Immunol 176:5529-5537.
27. Liu P, Jamaluddin M, Li K, Garofalo R P, Casola A, Brasier AR. 2007. Retinoic acid-inducible gene I mediates early antiviral response and Toll-like receptor 3 expression in respiratory syncytial virusinfected airway epithelial cells. J Virol 81:1401-1411.
28. Majde JA. 2000. Viral double-stranded RNA, cytokines, and the flu. J Interferon Cytokine Res 20:259-272.
29. Majde JA, Brown RK, Jones MW, Dieffenbach CW, Maitra N, Krueger JM, Cady AB, Smitka CW, Maassab HF. 1991. Detection of toxic viral-associated double-stranded RNA (dsRNA) in influenzainfected lung. Microb Pathog 10:105-115.
30. Merolla R, Rebert NA, Tsiviste PT, Hoffmann SP, Panuska JR. 1995. Respiratory syncytial virus replication in human lung epithelial cells: inhibition by tumor necrosis factor alpha and interferon beta. Am J Respir Crit Care Med 152:1358-1366.
31. Miettinen M, Sareneva T, Julkunen I, Matikainen S. 2001. IFNs activate toll-like receptor gene expression in viral infections. Genes Immun 2:349-355.
32. Monick MM, Yarovinsky TO, Powers LS, Butler NS, Carter AB, Gudmundsson G, Hunninghake GW. 2003. Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem 278:53035-53044.
33. Murawski MR, Bowen GN, Cerny AM, Anderson LJ, Haynes LM, Tripp RA, Kurt-Jones EA, Finberg RW. 2009. Respiratory syncytial virus activates innate immunity through Toll-like receptor 2. J Virol 83:1492-1500.
34. Ottolini MG, Blanco JC, Eichelberger MC, Porter DD, Pletneva L, Richardson JY, Prince GA. 2005. The cotton rat provides a useful small-animal model for the study of influenza virus pathogenesis. J Gen Virol 86:2823-2830.
35. Ottolini M, Blanco J, Porter D, Peterson L, Curtis S, Prince G. 2003. Combination anti-inflammatory and antiviral therapy of influenza in a cotton rat model. Pediatr Pulmonol 36:290-294.
36. Pletneva LM, Haller O, Porter DD, Prince GA, Blanco JC. 2006. Interferon-inducible Mx gene expression in cotton rats: cloning, characterization, and expression during influenza viral infection. J Interferon Cytokine Res 26:914-921.
37. Pletneva LM, Haller O, Porter DD, Prince GA, Blanco JC. 2008. Induction of type I interferons and interferon-inducible Mx genes during respiratory syncytial virus infection and reinfection in cotton rats. J Gen Virol 89:261-270.
38. Prince GA, Curtis SJ, Yim KC, Porter DD. 2001. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82:2881-2888.
39. Prince GA, Hemming VG, Horswood RL, Chanock RM. 1985. Immunoprophylaxis and immunotherapy of respiratory syncytial virus infection in the cotton rat. Virus Res 3:193-206.
40. Prince GA, Jenson AB, Horswood RL, Camargo E, Chanock RM. 1978. The pathogenesis of respiratory syncytial virus infection in cotton rats. Am J Pathol 93:771-791.
41. Prince GA, Mathews A, Curtis SJ, Porter DD. 2000. Treatment of respiratory syncytial virus bronchiolitis and pneumonia in a cotton rat model with systemically administered monoclonal antibody (Palivizumab) and glucocorticosteroid. J Infect Dis 182:1326-1330.
42. Ramaswamy M, Shi L, Varga SM, Barik S, Behlke MA, Look DC. 2006. Respiratory syncytial virus nonstructural protein 2 specifically inhibits type I interferon signal transduction. Virology 344:328-339.
43. Reed JL, Brewah YA, Delaney T, Welliver T, Burwell T, Benjamin E, Kuta E, Kozhich A, McKinney L, Suzich J, Kiener PA, Avendano L, Velozo L, Humbles A, Welliver RC, Sr., Coyle AJ. 2008. Macrophage impairment underlies airway occlusion in primary respiratory syncytial virus bronchiolitis. J Infect Dis 198:1783-1793.
44. Ritter M, Mennerich D, Weith A, Seither P. 2005. Characterization of Toll-like receptors in primary lung epithelial cells: strong impact of the TLR3 ligand poly (I:C) on the regulation of Toll-like receptors, adaptor proteins and inflammatory response. J Inflamm (Lond) 2:16.
45. Rudd BD, Burstein E, Duckett CS, Li X, Lukacs NW. 2005. Differential role for TLR3 in respiratory syncytial virus-induced chemokine expression. J Virol 79:3350-3357.
46. Salazar AM, Levy HB, Ondra S, Kende M, Scherokman B, Brown D, Mena H, Martin N, Schwab K, Donovan D, Dougherty D, Pulliam M, Ippolito M, Graves M, Brown H, Ommaya A. 1996. Long-term treatment of malignant gliomas with intramuscularly administered polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethylcellulose: an open pilot study. Neurosurgery 38:1096-1103.
47. Samuel CE. 2001. Antiviral actions of interferons. Clin Microbiol Rev 14:778-809.
48. Schlender J, Hornung V, Finke S, Gunthner-Biller M, Marozin S, Brzozka K, Moghim S, Endres S, Hartmann G, Conzelmann KK. 2005. Inhibition of toll-like receptor 7- and 9-mediated alpha/beta interferon production in human plasmacytoid dendritic cells by respiratory syncytial virus and measles virus. J Virol 79:5507-5515.
49. Smith PL, Lombardi G, Foster GR. 2005. Type I interferons and the innate immune response-more than just antiviral cytokines. Mol Immunol 42:869-877.
50. Sperber SJ, Hayden FG. 1989. Comparative susceptibility of respiratory viruses to recombinant interferons-alpha 2b and -beta. J Interferon Res 9:285-293.
51. Traynor TR, Majde JA, Bohnet SG, Krueger JM. 2004. Intratracheal double-stranded RNA plus interferon-gamma: a model for analysis of the acute phase response to respiratory viral infections. Life Sci 74:2563-2576.
52. Weber F, Wagner V, Rasmussen SB, Hartmann R, Paludan SR. 2006. Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses. J Virol 80:5059-5064.
53. Welliver RC. 2003. Respiratory syncytial virus and other respiratory viruses. Pediatr Infect Dis J 22: S6-S10;
54. discussion S10-S12.
55. Welliver TP, Reed JL, Welliver RC, Sr. 2008. Respiratory syncytial virus and influenza virus infections: observations from tissues of fatal infant cases. Pediatr Infect Dis J 27: S92-S96.
56. Wong JP, Saravolac EG, Sabuda D, Levy HB, Kende M. 1995. Prophylactic and therapeutic efficacies of poly (IC. LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother 39:2574-2576.
57. Wong J P, Yang H, Nagata L, Kende M, Levy H, Schnell G, Blasetti K. 1999. Liposome-mediated immunotherapy against respiratory influenza virus infection using double-stranded RNA poly ICLC. Vaccine 17:1788-1795.
58. Zheng BJ, Chan KW, Lin Y P, Zhao GY, Chan C, Zhang HJ, Chen HL, Wong SS, Lau SK, Woo PC, Chan KH, Jin DY, Yuen KY. 2008. Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus. Proc Natl Acad Sci USA 105:8091-8096.